Onco-Innovations Advances PNKP Inhibitor Scale-Up with Dalton Partnership

Onco-Innovations Limited, a Vancouver-based oncology-focused company, has announced the initiation of process optimization and intermediate scale-up activities for its PNKP inhibitor technology, A83B4C63, with Dalton Pharma Services. The collaboration aims to refine and expand the synthesis process of the drug under non-GMP conditions, essential for future clinical material production.

Dalton Pharma Services, operating from Toronto, will leverage their expertise to enhance the manufacturing process for A83B4C63, focusing on analytical method qualification and process scale-up. These actions intend to ensure robust and reproducible manufacturing aligned with international quality standards.

The completion of this phase is crucial for Onco-Innovations as it advances towards meeting GMP production standards and supports future clinical studies targeting improved cancer treatment efficacy. The process includes comprehensive testing methods to ensure the safety and stability of the pharmaceutical ingredient.